203 related articles for article (PubMed ID: 27405694)
21. Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
Konuma T; Kato S; Ishii H; Oiwa-Monna M; Asano S; Tojo A; Takahashi S
Leuk Res; 2015 Jun; 39(6):625-31. PubMed ID: 25888304
[TBL] [Abstract][Full Text] [Related]
22. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
[TBL] [Abstract][Full Text] [Related]
23. [Peripheral blood stem cell transplantation for 53 patients with malignant hematologic diseases].
Xie XS; Wan DM; Sun H; Sun L; Liu LX; Jiang ZX
Ai Zheng; 2007 Apr; 26(4):403-6. PubMed ID: 17430661
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
25. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
[TBL] [Abstract][Full Text] [Related]
26. Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.
Nakamura Y; Tanaka Y; Tanaka M; Yamamoto K; Matsuguma M; Kajimura Y; Tokunaga Y; Yujiri T; Tanizawa Y
Transplant Proc; 2019 Apr; 51(3):896-900. PubMed ID: 30979482
[TBL] [Abstract][Full Text] [Related]
27. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
28. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Zheng R; Xie B; Wang C; Yu B; Xu J; Tan H
Ann Hematol; 2016 Jan; 95(1):157-159. PubMed ID: 26382274
[No Abstract] [Full Text] [Related]
29. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia.
Zheng C; Zhu X; Tang B; Yao W; Song K; Tong J; Geng L; Liu H; Sun Z
Ann Hematol; 2015 Mar; 94(3):473-80. PubMed ID: 25217231
[TBL] [Abstract][Full Text] [Related]
31. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
32. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
33. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
35. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
36. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
37. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
Cassileth PA; Lee SJ; Litzow MR; Miller KB; Stadtmauer EA; Tallman MS; Lazarus HM; Bennett JM; Paietta E; Dewald GW; Rowe JM;
Leuk Lymphoma; 2005 Jan; 46(1):55-61. PubMed ID: 15621781
[TBL] [Abstract][Full Text] [Related]
38. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
[TBL] [Abstract][Full Text] [Related]
39. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
40. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]